Summary: | CADTH will undertake a systematic review to compare the efficacy and safety of new and existing drug therapies for pulmonary arterial hypertension (PAH), and will examine their cost-effectiveness. The review will include drug therapies that are available in Canada (epoprostenol, treprostinil, bosentan, ambrisentan, macitentan, sildenafil, tadalafil) and one for which the clinical development program is advanced but is not yet approved for the treatment of PAH in Canada (riociguat). The clinical and cost-effectiveness evidence will be reviewed by the Canadian Drug Expert Committee (CDEC) for the purpose of making recommendations. Recommendations and advice delivered by CDEC are provided to CADTH participating jurisdictional drug programs to inform their policy decisions
|